TABLE 3.

Antiviral and Immunomodulatory Management during Hospitalization for COVID‐19

Characteristics	All patients	Survived	Died	p‐Value
	(n = 38)	(n = 27)	(n = 11)
Median tacrolimus trough during admission, ng/ml
Alternative therapy during admission	5 (13.2%)	4 (14.8%)	1 (9.1%)	.77
1.0‐5.0	10 (26.3%)	7 (25.9%)	3 (27.3%)
5.1‐10.0	19 (50.0%)	14 (51.9%)	5 (45.5%)
>10.0	4 (10.5%)	2 (7.4%)	2 (18.2%)
Percentage reduction in median tacrolimus trough
Alternative therapy prior to admission	6 (15.8%)	5 (18.5%)	1 (9.1%)	.83
No reduction	15 (39.5%)	10 (37.0%)	5 (45.5%)
10%‐30%	12 (31.6%)	8 (29.6%)	4 (36.4%)
>30%	5 (13.2%)	4 (14.8%)	1 (9.1%)
Percentage change in tacrolimus trough (IQR)	−11% (−26% to 17%)	−11% (−28% to 11%)	−6% (−22% to 33%)	.32
Mycophenolate dose
Off antimetabolite	4 (10.5%)	2 (7.4%)	2 (18.2%)	.68
Same dose	1 (2.6%)	1 (3.7%)	0 (0.0%)
50%‐75% dose reduction	20 (52.6%)	14 (51.9%)	6 (54.5%)
Hold antimetabolite	13 (34.2%)	10 (37.0%)	3 (27.3%)
Total prednisone equivalents administered during hospitalization, mg
<500	25 (65.8%)	20 (74.1%)	5 (45.5%)	.15
500‐1000	8 (21.1%)	5 (18.5%)	3 (27.3%)
>1000	5 (13.2%)	2 (7.4%)	3 (27.3%)
Mean prednisone equivalents per day during hospitalization, mg	17.2 ± 18.6	12.9 ± 16.5	27.7 ± 19.2	.04
Enrolled in clinical trial	4 (10.5%)	4 (14.8%)	0 (0.0%)	.18
Antiviral and immunomodulatory therapies
Hydroxychloroquine	26 (68.4%)	18 (66.7%)	8 (72.7%)	.71
Azithromycin	22 (57.9%)	14 (51.9%)	8 (72.7%)	.24
Remdesivir	3 (7.9%)	2 (7.4%)	1 (9.1%)	.86
IL‐6 or IL‐1 inhibitor	3 (7.9%)	2 (7.4%)	1 (9.1%)	.86
Convalescent plasma	10 (26.3%)	6 (22.2%)	4 (36.4%)	.37
Anticoagulation therapy
None	2 (5.3%)	1 (3.7)	1 (9.1%)	.37
Prophylactic dose	16 (42.1%)	13 (48.1%)	3 (27.3%)
Treatment dose	20 (52.6%)	13 (48.1%)	7 (63.6%)
Prescription of anti‐Xa inhibitor	10 (26.3%)	8 (29.6%)	2 (18.2%)	.46